Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
48
SVA Quote, Financials, Valuation and Earnings
Last price:
$6.47
Seasonality move
:
13.44%
Day range:
$6.47 - $6.47
52-week range:
$6.25 - $6.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.05x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$464.9M
Revenue:
$448.3M
EPS (TTM):
-$1.31
Analysts' Opinion
-
Consensus RatingSinovac Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Sinovac Biotech has an estimated downside of -- from its current price of $6.47.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $6.47.
Fair Value
-
According to the consensus of 0 analysts, Sinovac Biotech has -- downside to fair value with a price target of -- per share.
SVA vs. S&P 500
-
Over the past 5 trading days, Sinovac Biotech has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sinovac Biotech does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sinovac Biotech has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Sinovac Biotech reported revenues of --.
Earnings Growth
-
Sinovac Biotech has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Sinovac Biotech reported earnings per share of --.
Enterprise value:
-6.9B
EV / Invested capital:
--
Price / LTM sales:
1.50x
EV / EBIT:
--
EV / Revenue:
-16.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$395.3M
Return On Assets:
-0.93%
Net Income Margin (TTM):
-29.06%
Return On Equity:
-1.05%
Return On Invested Capital:
-1.02%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2019-12-31 | 2020-12-31 | |
| Income Statement | ||||||
| Revenue | $229.7M | $246.1M | $510.6M | $81.1M | $327.5M | |
| Gross Profit | -- | -- | -- | $68.9M | $283.9M | |
| Operating Income | -- | -- | -- | $28.9M | $197M | |
| EBITDA | -- | -- | -- | $30.9M | $200M | |
| Diluted EPS | -- | -- | -- | $0.20 | $0.96 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $338M | $11.7B | $13.1B | $11.8B | $11.1B | |
| Total Assets | $529.4M | $12.6B | $15.1B | $13.7B | $12.9B | |
| Current Liabilities | $113.5M | $3.3B | $564.9M | $1.2B | $978.5M | |
| Total Liabilities | $191.4M | $3.5B | $971.9M | $1.5B | $1.4B | |
| Total Equity | $338M | $9.1B | $14.1B | $12.2B | $11.5B | |
| Total Debt | -- | $54.4M | $18.2M | $216.3M | $309.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2019-12-31 | 2020-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.9M | $39.1M | $479.3M | $26.5M | $481.1M | |
| Cash From Investing | -- | -- | -- | -$32.3M | -$152.2M | |
| Cash From Financing | -- | -- | -- | $2.8M | $541.6M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SVA
Sector
Market Cap
$464.9M
$44.6M
Price % of 52-Week High
98.33%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
--
-29.09%
Beta (5-Year)
0.000
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$6.47
200-day SMA
Sell
Level
$6.47
Bollinger Bands (100)
Sell
Level
6.47 - 6.47
Chaikin Money Flow
Sell
Level
-62.8M
20-day SMA
Sell
Level
$6.47
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$6.47
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
192.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.1169)
Sell
Beneish M-Score
(Annual)
Level (-1.9076)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-4.8836)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Stock Forecast FAQ
In the current month, SVA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SVA average analyst price target in the past 3 months is --.
-
Where Will Sinovac Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sinovac Biotech share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Sinovac Biotech?
Analysts are divided on their view about Sinovac Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sinovac Biotech is a Sell and believe this share price will rise from its current level to --.
-
What Is Sinovac Biotech's Price Target?
The price target for Sinovac Biotech over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sinovac Biotech is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SVA?
You can purchase shares of Sinovac Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sinovac Biotech shares.
-
What Is The Sinovac Biotech Share Price Today?
Sinovac Biotech was last trading at $6.47 per share. This represents the most recent stock quote for Sinovac Biotech. Yesterday, Sinovac Biotech closed at $6.47 per share.
-
How To Buy Sinovac Biotech Stock Online?
In order to purchase Sinovac Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
